Clinical Trial Detail

NCT ID NCT02674061
Title Efficacy and Safety Study of Pembrolizumab (MK-3475) in Women With Advanced Recurrent Ovarian Cancer (MK-3475-100/KEYNOTE-100)
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

fallopian tube cancer

peritoneum cancer

ovary epithelial cancer

Therapies

Pembrolizumab

Age Groups: adult

No variant requirements are available.